Taro Pharmaceutical Industries (TARO) Getting Somewhat Positive Press Coverage, Study Shows

Media headlines about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive on Sunday, according to Accern. The research firm ranks the sentiment of media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 46.0570713777351 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Shares of Taro Pharmaceutical Industries (TARO) opened at $106.99 on Friday. The stock has a market capitalization of $4,347.04, a P/E ratio of 13.21 and a beta of 0.63. Taro Pharmaceutical Industries has a fifty-two week low of $94.00 and a fifty-two week high of $128.46.

A number of research analysts recently weighed in on TARO shares. BidaskClub raised Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a research note on Saturday, September 9th. TheStreet downgraded Taro Pharmaceutical Industries from a “b-” rating to a “c+” rating in a research note on Wednesday, August 9th.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/12/03/taro-pharmaceutical-industries-taro-getting-somewhat-positive-press-coverage-study-shows.html.

About Taro Pharmaceutical Industries

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Insider Buying and Selling by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply